¼¼°èÀÇ ¹ÌÅ丶À̽нÃÀå
Mitomycin
»óǰÄÚµå : 1795959
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÌÅ丶À̽м¼°è ½ÃÀåÀº 2030³â±îÁö 2¾ï 8,440¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 8,590¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÌÅ丶À̽м¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 7.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 8,440¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ º´¿ø ¾à±¹Àº CAGR 5.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 1,510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àü¹® ¾à±¹ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5,070¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÌÅ丶À̽нÃÀåÀº 2024³â¿¡ 5,070¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5,900¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 11.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.8%¿Í 7.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹ÌÅ丶À̽нÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹ÌÅ丶À̽ÅÀÌ Á¾¾çÇÐ ¹× º¸Á¶¿ä¹ý¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°­·ÂÇÑ DNA °¡±³ Ç×¾ÏÁ¦ÀÎ ¹ÌÅ丶À̽ÅÀº 50³â ÀÌ»ó ÀÓ»óÀûÀ¸·Î Áß¿äÇÑ Ä¡·á È­ÇÕ¹°·Î »ç¿ëµÇ¾î ¿Ô½À´Ï´Ù. ÀüÅëÀûÀ¸·Î ¼ÒÈ­±â¾Ï, ¹æ±¤¾Ï, À¯¹æ¾Ï Ä¡·á¿¡ »ç¿ëµÇ¾î ¿ÔÁö¸¸, ±¹¼Ò ¾Ï Ä¡·á, º´¿ë È­Çпä¹ý, ¾È°úÀû Ä¡·á¿¡¼­ ¿ªÇÒÀÌ È®´ëµÇ¸é¼­ ¹ÌÅ丶À̽ÅÀÌ ´Ù½Ã ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ±âÁ¸ È­Çпä¹ýÀÌ Á¾Á¾ ½ÇÆÐÇÏ´Â Àú»ê¼Ò¼º Á¾¾ç ºÎÀ§¸¦ Ç¥ÀûÀ¸·Î »ï´Â È¿´ÉÀº 1Â÷ ¼±Åà ¾àÁ¦¿¡ ³»¼ºÀÌ ÀÖ´Â Á¾¾ç À¯Çü¿¡ ´ëÇÑ Æ´»õ ¾à¹°·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¹æ±¤³» Åõ¿©´Â ºñ±ÙÀ°Ä§À±¼º ¹æ±¤¾Ï(NMIBC)ÀÇ 1Â÷ Ä¡·á ¹× °æ¿äµµÀû ÀýÁ¦¼ú ÈÄ ¿¹¹æ¿ä¹ýÀ¸·Î ÇöÀç Ç¥ÁØÀûÀÎ Á¢±Ù¹ýÀÌ µÇ¾ú½À´Ï´Ù. ÃÖ±Ù °Ö ±â¹Ý Á¦Á¦, ³ª³ëÀÔÀÚ Ä¸½¶È­ µî ¾à¹°Àü´Þ ¹æ¹ýÀÇ °³¼±À¸·Î ¾à¹° ü·ù½Ã°£°ú ºÎÀ§º° »ýü ÀÌ¿ë·üÀÌ ´õ¿í °³¼±µÇ¾î Àü½Å µ¶¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¹ÌÅ丶À̽ÅÀ» ´õ¿í È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¹ÌÅ丶À̽ÅÀÇ ÀÓ»óÀû À¯¿ë¼ºÀ» È®´ëÇÏ´Â Á¦Çü°ú Åõ¿© ¹æ¹ýÀÇ ¹ßÀüÀº?

Á¦ÇüÈ­ ±â¼ú Çõ½ÅÀº ¹ÌÅ丶À̽ÅÀÇ ÀÓ»óÀû À¯¿ë¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¹ÌÅ丶À̽ŠC °Ö(UroGen PharmaÀÇ Jelmyto µî)ÀÇ °³¹ßÀº Ä¡·á ¿É¼ÇÀÌ Á¦ÇѵǾî ÀÖ´Â »óºÎ¿ä·Î»óÇǾÏ(UTUC)¿¡ »õ·Î¿î ±æÀ» ¿­¾îÁÖ¾ú½À´Ï´Ù. ÀÌ ¼­¹æÇü Á¦Á¦´Â Á¡¸·¿¡ Àå½Ã°£ Á¢ÃËÇÒ ¼ö ÀÖ¾î ±âÁ¸ ¾×»ó ÁÖ»çÁ¦º¸´Ù È¿´ÉÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ ½ÅÀåÀ» º¸Á¸ÇÏ´Â Ä¡·á¿¡¼­ ÁÁÀº °á°ú¸¦ ¾ò¾úÀ¸¸ç, ºñ´¢±â°ú ¿µ¿ª¿¡¼­ äÅÃÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¹ÌÅ丶À̽ÅÀÇ ¾È°ú, ƯÈ÷ ³ì³»Àå ÇÊÅÍ ¼ö¼ú°ú ÀÍ»óÆí ÀýÁ¦¼ú¿¡¼­ ¹ÌÅ丶À̽ÅÀÇ »ç¿ëÀº Ç×¼¶À¯È­ Ư¼ºÀ¸·Î ÀÎÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú Áß Àû¿ëÇÔÀ¸·Î½á ÈäÅÍ Çü¼ºÀ» ¹æÁöÇÏ°í ¼ö¼ú °á°úÀÇ Àå±âÀûÀÎ ¼º°ø·üÀ» ³ôÀÔ´Ï´Ù. ¶ÇÇÑ, ¹ÌÅ丶À̽ÅÀº ƯÈ÷ ´ëÀåÁ÷Àå ¹× ¸ÍÀå À¯·¡ º¹¸·¾ÏÁ¾Áõ¿¡ ´ëÇÑ °¡¿­È­Çпä¹ý(HIPEC) ÇÁ·ÎÅäÄÝ¿¡¼­ Á¾¾ç ÀýÁ¦ ÈÄ ±¹¼ÒÀû ¼¼Æ÷µ¶¼ºÀÌ ÇÊ¿äÇÑ º¹°­ ³» ¶Ç´Â º¹°­ ³»·Î »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ Á¤¹Ð¼º¿¡ ±â¹ÝÇÑ ÀÀ¿ëÀº ÀÌ ¿À·¡µÈ È­Çпä¹ý¿¡ ´ëÇÑ °ü½ÉÀ» ´Ù½Ã ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

¿¬±¸ÁøÀº ¶ÇÇÑ ¸®Æ÷¼Ø Àü´Þ ¸ÞÄ¿´ÏÁò°ú Ç÷°ü ¹× ±¸È¹ÀÌ ÀÖ´Â Á¾¾ç ºÎÀ§¿¡¼­ Á¶ÀýµÈ Àå±â ³ëÃâÀ» À§ÇØ ¹ÌÅ丶À̽ÅÀ» À̽ÄÇÑ »ýºÐÇØ¼º ÀÓÇöõÆ®¸¦ Ž»öÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ä¡·á È¿´ÉÀ» À¯ÁöÇϰųª Çâ»ó½ÃŰ¸é¼­ Àü½Å ºÎÀÛ¿ëÀ» ÁÙÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, ¹ÌÅ丶À̽ÅÀ» Çö´ë Á¤¹Ð Á¾¾çÇÐÀÇ Æ²¿¡ ÅëÇÕÇÒ ¼ö ÀÖ´Â È帷ΠÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¹ÌÅ丶À̽мö¿ä¸¦ ÁÖµµÇÏ´Â ¼¼°è ½ÃÀå°ú ÀÓ»ó ºÐ¾ß´Â?

¹Ì±¹°ú À¯·´¿¬ÇÕÀÌ ¹ÌÅ丶À̽ÅÀÇ °¡Àå Å« ½ÃÀåÀ¸·Î ³²¾ÆÀÖ´Â ÀÌÀ¯´Â È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ¹æ±¤¾Ï Ä¡·á¿¡ ´ëÇÑ º¸Çè±Þ¿© Àû¿ë, ÃÖ¼Òħ½ÀÀû ¼ö¼ú º¸Á¶±â±¸ÀÇ Ã¤Åà Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. UTUC¿ë ¹ÌÅ丶À̽ŠC Á©°ú °°Àº »õ·Î¿î Á¦Á¦ÀÇ FDA ½ÂÀÎÀº º´¿ø°ú ¿Ü·¡ ȯÀÚ ¼¾ÅÍ¿¡¼­ ÀÏ»óÀûÀÎ Á¾¾ç ÀýÁ¦¼ú ÇÁ·ÎÅäÄÝ¿¡ äÅÃÇÔÀ¸·Î½á ºñ´¢±â°ú ¿µ¿ª¿¡¼­ ¾à¹°ÀÇ ¹ßÀÚÃ븦 ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ÀϺ», Çѱ¹, Áß±¹ µîÀÌ ´ëÀå¾Ï, °£¾Ï, ÃéÀå¾Ï Ä¡·á¿¡ ¹ÌÅ丶À̽Š»ç¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¾Ï ¹ßº´·üÀÇ Áõ°¡¿Í ¼ö¼ú Áß È­Çпä¹ý ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ¸·Î ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ Áö¿ª Á¦Á¶¾÷ü¿¡¼­ ¹ÌÅ丶À̽ÅÀÇ Á¦³×¸¯ ÀǾàǰÀ» »ý»êÇϰí ÀÖ¾î Àú·ÅÇÑ °¡°ÝÀ¸·Î ±¸ÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ Àεµ ½ÃÀå¿¡¼­´Â °øÁß º¸°Ç ȯ°æ¿¡¼­ ºñ¿ë È¿À²ÀûÀÎ È­Çпä¹ýÀÇ ÀÏȯÀ¸·Î ¹ÌÅ丶À̽ſ¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

À̽º¶ó¿¤, µ¶ÀÏ µî ¿¬±¸ Á᫐ ½ÃÀå¿¡¼­´Â Èñ±ÍÀ°Á¾, ¾È±¸Ç¥¸éÁ¾¾ç µî »õ·Î¿î ÀûÀÀÁõÀ» ¿¬±¸Çϰí ÀÖÀ¸¸ç, ¹ÌÅ丶À̽Űú üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦, ¹æ»ç¼± Ä¡·á °¨ÀÛÁ¦ µî°úÀÇ º´¿ë¿ä¹ý ½ÃÇè¿¡µµ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. º´¿ø Á¾¾çÇаú, ¿Ü°ú Á¾¾çÇаú, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ´Â ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ¿¡¼­ ÀÌ ¾à¹°ÀÇ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚÀÔ´Ï´Ù.

¼¼°è ¹ÌÅ丶À̽нÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹ÌÅ丶À̽м¼°è ½ÃÀå ¼ºÀåÀº ¹æ±¤¾Ï ¹× ¼ÒÈ­±â¾Ï ¹ßº´·ü Áõ°¡, ±¹¼Ò È­Çпä¹ý Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾È°ú ¹× ¿Ü°ú º¸Á¶¿ä¹ý¿¡¼­ÀÇ »ç¿ë È®´ë µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÌ È­ÇÕ¹°Àº ¾Ï, ¾È°ú, ¿Ü°ú µîÀÇ Ä¡·á ¿µ¿ª¿¡¼­ ¹ü¿ë¼ºÀÌ ÀÖ¾î »õ·Î¿î Ç×¾ÏÁ¦ÀÇ µîÀå¿¡µµ ºÒ±¸Çϰí ÀÓ»óÀû À¯È¿¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù.

Â÷¼¼´ë Á¦Á¦¿¡ ´ëÇÑ ±ÔÁ¦Àû Áö¿ø°ú Àå±â º¸Á¸ Ä¡·á ÆÐ·¯´ÙÀÓÀ¸·ÎÀÇ Áö¼ÓÀûÀÎ ÀüȯÀº ƯÈ÷ °í·ÉÀÚ ¹× °íÀ§Çè ¼ö¼ú ȯÀÚµéÀ» ´ë»óÀ¸·Î ÇÑ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ¾Ï ¿¬±¸ °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ±¹¼Ò Åõ¿© Ç÷§ÆûÀ» ÅëÇÑ ¹ÌÅ丶À̽ÅÀÇ ¸ÂÃã Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ ÅëÇÕÀÌ Áõ°¡ÇÔ¿¡ µû¶ó µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½ÅÈï±¹¿¡¼­ÀÇ Á¢±Ù¼º Áõ°¡, Á¦³×¸¯ ÀǾàǰÀÇ °¡¿ë¼º, Æ´»õ ¾ÏÁ¾¿¡ ´ëÇÑ ÁÁÀº ÀÓ»ó °á°ú µîÀÌ »ó¾÷Àû ÀáÀç·ÂÀ» È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. ¾à¹° °³¹ßÀÚµéÀÌ µ¶¼ºÀ» ÁÙÀ̰í Ç¥ÀûÀ» °³¼±ÇÏ´Â ÀçÁ¦Çü¿¡ ÁýÁßÇϰí ÀÖ´Â °¡¿îµ¥, ¹ÌÅ丶À̽ÅÀº ÀÓ»óÀû À¯¿ë¼ºÀ» È®ÀåÇÏ°í ¼¼°è ÇコÄÉ¾î ½Ã½ºÅÛ¿¡¼­ Àü·«Àû °ü·Ã¼ºÀ» ÀçÈ®ÀÎÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

¾Ï(¼ÒÈ­±â¾Ï, ¹æ±¤¾Ï, Æó¾Ï, À¯¹æ¾Ï, µÎ°æºÎ¾Ï, ±âŸ ¾Ï), Åõ¿© °æ·Î(Á¤¸Æ³» Åõ¿©, ¹æ±¤³» Åõ¿©, ±âŸ Åõ¿© °æ·Î), À¯Åë ä³Î(º´¿ø ¾à±¹, Àü¹® ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ À¯Åë ä³Î), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ¾Ï ¿¬±¸ ±â°ü ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Mitomycin Market to Reach US$284.4 Million by 2030

The global market for Mitomycin estimated at US$185.9 Million in the year 2024, is expected to reach US$284.4 Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$115.1 Million by the end of the analysis period. Growth in the Specialty Pharmacies segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.7 Million While China is Forecast to Grow at 11.2% CAGR

The Mitomycin market in the U.S. is estimated at US$50.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$59.0 Million by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Mitomycin Market - Key Trends & Drivers Summarized

Why Is Mitomycin Regaining Attention in Oncology and Adjunct Therapies?

Mitomycin, a potent DNA cross-linking antineoplastic agent, has remained a clinically relevant therapeutic compound for over five decades. Traditionally employed in the treatment of gastrointestinal, bladder, and breast cancers, mitomycin is witnessing renewed attention owing to its expanding role in localized cancer therapies, combination chemotherapy regimens, and ophthalmologic procedures. Its efficacy in targeting hypoxic tumor zones, where conventional chemotherapies often fail, is positioning it as a niche agent for tumor types resistant to first-line drugs.

Intravesical mitomycin instillation is now a standard approach in non-muscle invasive bladder cancer (NMIBC), where it serves both as a primary treatment and as a prophylactic agent post transurethral resection. Recent enhancements in drug delivery methods, including gel-based formulations and nanoparticle encapsulation, are further improving drug retention time and site-specific bioavailability, making mitomycin more effective while minimizing systemic toxicity.

What Formulations and Administration Advances Are Expanding Mitomycin’s Clinical Utility?

Technological innovation in drug formulation is expanding mitomycin’s clinical reach. The development of mitomycin C gel (such as UroGen Pharma’s Jelmyto) has opened new avenues in upper tract urothelial carcinoma (UTUC), a disease area with limited treatment options. This sustained-release formulation allows prolonged mucosal contact and improves efficacy over conventional liquid instillations. Clinical trials have shown positive outcomes in kidney-sparing interventions, bolstering adoption in urology.

Mitomycin's use in ophthalmology, particularly in glaucoma filtering surgeries and pterygium excision, is driven by its anti-fibrotic properties. When applied intraoperatively, it prevents scarring and increases the long-term success rates of surgical outcomes. Additionally, mitomycin is used intra-abdominally or intraperitoneally in heated chemotherapy (HIPEC) protocols for peritoneal carcinomatosis, especially from colorectal or appendiceal origins, where localized cytotoxicity is needed post-tumor debulking. Such precision-based applications are reviving interest in this otherwise older chemotherapeutic class.

Researchers are also exploring liposomal delivery mechanisms and biodegradable implants embedded with mitomycin for controlled, long-term exposure in highly vascularized or compartmental tumor sites. These innovations aim to reduce systemic side effects while maintaining or improving therapeutic potency, positioning mitomycin as a candidate for integration into modern precision oncology frameworks.

Which Global Markets and Clinical Domains Are Driving Demand for Mitomycin?

The United States and European Union remain the largest markets for mitomycin, owing to established regulatory frameworks, reimbursement coverage for bladder cancer therapies, and increasing adoption of minimally invasive surgical adjuncts. FDA approvals for newer formulations such as mitomycin C gel for UTUC have expanded the drug’s footprint within urology, with hospitals and outpatient centers adopting it for routine tumor ablation protocols.

In Asia-Pacific, countries like Japan, South Korea, and China are expanding mitomycin utilization in colorectal, liver, and pancreatic cancer treatment pathways. Rising cancer incidence and greater access to intraoperative chemotherapy facilities have elevated demand. Several regional manufacturers are also producing generic mitomycin variants, improving affordability and access. The Indian market, in particular, is seeing increased demand for mitomycin as part of cost-effective chemotherapy regimens in public health settings.

Research-focused markets such as Israel and Germany are investigating newer indications, including rare sarcomas and ocular surface tumors, while also focusing on combination therapy trials where mitomycin is paired with checkpoint inhibitors or radiotherapy sensitizers. Hospital oncology departments, surgical oncology units, and ambulatory infusion centers are key end users of the drug in both established and emerging economies.

What Is Fueling Growth in the Global Mitomycin Market?

The growth in the global mitomycin market is driven by several factors, including rising incidence of bladder and gastrointestinal cancers, increasing demand for localized chemotherapy delivery systems, and expanding application in ophthalmic and surgical adjunct therapies. The compound’s versatility across therapeutic areas-oncology, ophthalmology, and surgery-has enabled it to maintain clinical relevance despite the advent of newer anticancer agents.

Regulatory support for next-generation formulations and an ongoing shift toward organ-sparing treatment paradigms are bolstering its adoption, especially in elderly and high-risk surgical patients. Market growth is also supported by rising investment in oncology R&D pipelines and increasing integration of mitomycin into personalized care regimens via localized delivery platforms.

Moreover, growing access in emerging economies, the availability of generics, and favorable clinical outcomes in niche cancer types are solidifying its commercial viability. As drug developers focus on reformulations that reduce toxicity and improve targeting, mitomycin is poised for expanded clinical utility and renewed strategic relevance across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Mitomycin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer (Gastrointestinal Cancer, Bladder Cancer, Lung Cancer, Breast Cancer, Head & Neck Cancer, Other Cancers); Administration Route (Intravenous Administration, Intravesical Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Distribution Channel); End-User (Hospitals & Clinics End-User, Ambulatory Surgery Centers End-User, Cancer Research Institutes End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â